Rika Wakao

1.3k total citations · 1 hit paper
18 papers, 914 citations indexed

About

Rika Wakao is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Rika Wakao has authored 18 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Immunology and 6 papers in Oncology. Recurrent topics in Rika Wakao's work include CAR-T cell therapy research (4 papers), Immune Cell Function and Interaction (4 papers) and T-cell and B-cell Immunology (3 papers). Rika Wakao is often cited by papers focused on CAR-T cell therapy research (4 papers), Immune Cell Function and Interaction (4 papers) and T-cell and B-cell Immunology (3 papers). Rika Wakao collaborates with scholars based in Japan, Sweden and United Kingdom. Rika Wakao's co-authors include Mitsuhiro Endoh, Miguel Vidal, Haruhiko Koseki, Tatyana B. Nesterova, Ruth Appanah, Neil Brockdorff, Jacqueline E. Mermoud, José Silva, Amy Tang and Arie P. Otte and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and The FASEB Journal.

In The Last Decade

Rika Wakao

17 papers receiving 905 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polycomb Group Proteins Ring1A/B Link Ubiquitylation of Histone H2A to Heritable Gene Silencing and X Inactivation

2004 728 citations Jacqueline E. Mermoud, Rika Wakao et al. Developmental Cell profile →

Peers

Countries citing papers authored by Rika Wakao

Since Specialization

Citations

This map shows the geographic impact of Rika Wakao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rika Wakao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rika Wakao more than expected).

Fields of papers citing papers by Rika Wakao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rika Wakao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rika Wakao. The network helps show where Rika Wakao may publish in the future.

Co-authorship network of co-authors of Rika Wakao

This figure shows the co-authorship network connecting the top 25 collaborators of Rika Wakao. A scholar is included among the top collaborators of Rika Wakao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rika Wakao. Rika Wakao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	In vivo CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to address 2023 ·Frontiers in Medicine ·Rika Wakao, (unknown)	13
2	Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan 2022 ·BMC Health Services Research ·(unknown), Jun Sato, Rika Wakao, Takahiro Nonaka	0
3	The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in Japan 2021 ·Drug Safety ·Rika Wakao, Ingrid Lönnstedt, Yasunori Aoki, Rebecca E. Chandler	6
4	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity 2021 ·Frontiers in Medicine ·(unknown), (unknown), Hajime Sasaki, Mayumi Shikano, Rika Wakao	3
5	Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting 2020 ·Drug Safety ·(unknown), (unknown), (unknown), (unknown), Rebecca E. Chandler, H. Taavola, G. Niklas Norén, Rika Wakao	23
6	Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDA’s perspective 2020 ·Journal of Artificial Organs ·Nobuhiro Handa, (unknown), Yasuhiro Fujiwara, (unknown), Rika Wakao, Hiroyuki Arai	3
7	PMDA’s Vision for Horizon Scanning of Emerging Technologies Potentially Relevant to the Development of New Medical Products: The Regulatory Challenge 2020 ·Clinical Pharmacology & Therapeutics ·(unknown), Daisaku Sato, Rika Wakao, Hiroyuki Arai	5
8	Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports 2019 ·Drug Safety ·Rika Wakao, H. Taavola, (unknown), (unknown), (unknown), Rebecca E. Chandler, G. Niklas Norén	32
9	Mucosal-Associated Invariant T Cells in Regenerative Medicine 2017 ·Frontiers in Immunology ·Hiroshi Wakao, Chie Sugimoto, Shinzo Kimura, Rika Wakao	9
10	The dynamics of mucosal-associated invariant T cells in multiple sclerosis 2016 ·SpringerPlus ·Chie Sugimoto, Makoto Hirotani, Kazunori Yoshikiyo, Uichi Koshimizu, Rika Wakao, Takahiro Horinouchi, Yuichi Mazaki, (unknown), Toshiyuki Fukazawa, Hiroyoshi Fujita, Hidenao Sasaki, Hiroshi Wakao	9
11	Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence 2016 ·Journal of Pharmacy & Pharmaceutical Sciences ·(unknown), (unknown), (unknown), (unknown), Rika Wakao, (unknown)	2
12	Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence 2016 ·Journal of Pharmacy & Pharmaceutical Sciences ·(unknown), (unknown), (unknown), (unknown), Rika Wakao, (unknown)	1
13	Mucosal-Associated Invariant T Cell Is a Potential Marker to Distinguish Fibromyalgia Syndrome from Arthritis 2015 ·PLoS ONE ·Chie Sugimoto, Takahiko Konno, Rika Wakao, Hiroko Fujita, Hiroyoshi Fujita, Hiroshi Wakao	29
14	Constitutively active Stat5A and Stat5B promote adipogenesis 2010 ·Environmental Health and Preventive Medicine ·Hiroshi Wakao, Rika Wakao, Atsushi Oda, Hiroyoshi Fujita	25
15	In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer 2008 ·The FASEB Journal ·Hiroshi Wakao, Rika Wakao, (unknown), Kazuya Iwabuchi, Atsushi Oda, Hiroyoshi Fujita	5
16	A Novel Mouse Model for Invariant NKT Cell Study 2007 ·The Journal of Immunology ·Hiroshi Wakao, Hiroshi Kawamoto, (unknown), Kimiko Inoue, Atsuo Ogura, Rika Wakao, Atsushi Oda, Hiroyoshi Fujita	17
17	Polycomb Group Proteins Ring1A/B Link Ubiquitylation of Histone H2A to Heritable Gene Silencing and X Inactivation breakdown → 2004 ·Developmental Cell ·(unknown), Jacqueline E. Mermoud, Rika Wakao, Amy Tang, Mitsuhiro Endoh, Ruth Appanah, Tatyana B. Nesterova, José Silva, Arie P. Otte, Miguel Vidal, Haruhiko Koseki, Neil Brockdorff	728
18	Roles of Shc Signaling in Oxidative Stress Response and Aging 2004 ·Journal of Clinical Biochemistry and Nutrition ·Nozomu Mori, (unknown), Kiyoaki Sone, Yoshiaki Miyamoto, (unknown), Rika Wakao, Tomomi Ihara	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact